Calcipotriol Group for Alopecia Areata

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Wake Forest University Health Sciences, Winston-Salem, NC
Alopecia Areata+2 More
Calcipotriol - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.

Eligible Conditions

  • Alopecia Areata
  • Central Centrifugal Cicatricial Alopecia (CCCA)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alopecia Areata

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Month 2, Month 4, and Month 6

Baseline and Month 6
Dermatology Life Quality Index score
Month 6
Amount of hair regrowth
Month 6
Signs and symptoms of disease score
Month 6
Amount of hairline stabilization

Trial Safety

Safety Progress

1 of 3

Other trials for Alopecia Areata

Side Effects for

Hydrocortisone
7%Psoriasis
3%Nasopharyngitis
2%Headache
2%Erythema
1%Influenza
1%Pruritus
1%Rhinitis
1%Pyrexia
0%Upper limb fracture
0%Nausea
0%Burning sensation
0%Benign bone neoplasm
0%Cough
0%Tinnitus
0%Pneumonia
0%Chronic lymphocytic leukaemia
0%Panic disorder
0%Excoriation
0%Chest pain
0%Diverticulitis
0%Arthritis
0%Vertigo
0%Cardiac failure congestive
0%Cystitis acute
0%Respiratory tract infection viral
0%Rhinitis allergic
0%Depression
0%Cerebrovascular accident
0%Concussion
0%Application site pruritus
0%Deafness traumatic
0%Laryngeal neoplasm
0%Atrial fibrillation
0%Myocardial infarction
0%Back pain
0%Arthralgia
0%Hypertension
0%Upper respiratory tract infection
0%Viral infection
0%Gastroenteritis
0%Cervical vertebra injury
0%Contusion
0%Squamous cell carcinoma
0%Hypertensive crisis
0%Erysipelas
0%Clavicle fracture
0%Pregnancy
0%Cervix carcinoma stage 0
0%Bronchitis
0%Skin irritation
0%Postmenopausal haemorrhage
0%Herpes simplex
0%Knee operation
0%Toothache
0%Diarrhoea
This histogram enumerates side effects from a completed 2010 Phase 3 trial (NCT00691002) in the Hydrocortisone ARM group. Side effects include: Psoriasis with 7%, Nasopharyngitis with 3%, Headache with 2%, Erythema with 2%, Influenza with 1%.

Trial Design

2 Treatment Groups

Calcipotriol Group
1 of 2
Control Group
1 of 2
Experimental Treatment
Non-Treatment Group

10 Total Participants · 2 Treatment Groups

Primary Treatment: Calcipotriol Group · Has Placebo Group · Phase < 1

Calcipotriol Group
Drug
Experimental Group · 1 Intervention: Calcipotriol · Intervention Types: Drug
Control Group
Drug
ShamComparator Group · 1 Intervention: Subject's already prescribed drug · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Calcipotriol
2012
Completed Phase 3
~1920

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 2, month 4, and month 6
Closest Location: Wake Forest University Health Sciences · Winston-Salem, NC
2008First Recorded Clinical Trial
3 TrialsResearching Alopecia Areata
417 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.